Reuters logo
BRIEF-Vifor Pharma and Akebia announce license agreement to provide Vadadustat to Fresenius in U.S.
May 16, 2017 / 5:25 AM / 6 months ago

BRIEF-Vifor Pharma and Akebia announce license agreement to provide Vadadustat to Fresenius in U.S.

May 16 (Reuters) - Vifor Pharma

* Vifor Pharma and Akebia announce exclusive license agreement to provide Vadadustat to Fresenius medical care in the U.S. Upon FDA approval

* Will also make a $50 million equity investment in akebia at $14 per share

* Vifor pharma -entered into exclusive license agreement to sell vadadustat to fresenius medical care dialysis clinics in united states upon approval by u.s. Fda

* Vifor pharma will also make a $50 million equity investment in akebia at $14 per share

* Agreement is structured as a profit-sharing arrangement between akebia and vifor pharma

* Agreement is structured as a profit-sharing arrangement between akebia and vifor pharma

* Vifor pharma - arrangement subject to approval of vadadustat by fda and to inclusion of it in bundled reimbursement model, upon which akebia will receive $20 million payment from vifor Source text for Eikon: Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below